Table 6 The distubution of diplotype of CYP2C9 in CAD patient and control participants

1

1/1

0100/0100

CTAC/CTAC

47

52

1.511

0.893-2.557

0.122

1

40

28

0.824

0.421-1.611

0.334

0.334

7

24

0.251

0.105-0.876

0.004*

0.036*

2

1/2

0100/0000

CTAC/CCAC

72

59

0.858

0.576-1.278

0.451

1

53

25

1.437

0.839-2.462

0.149

0.745

19

34

0.419

0.218-0.806

0.016*

0.072

3

2/2

0000/0000

CCAC/CCAC

39

24

1.216

0.708-2.088

0.479

0.958

32

10

2.184

1.033-4.615

0.074

0.740

7

14

0.435

0.167-1.130

0.108

0.324

4

1/3

0100/0001

CTAC/CCAT

19

18

0.756

0.387-1.477

0.412

1

12

13

0.549

0.242-1.245

0.195

0.488

7

5

1.354

0.414-4.425

0.351

0.526

5

1/4

0100/0010

CTAC/CCCC

12

8

1.100

0.442-2.739

0.837

1

9

6

0.933

0.324-2.686

0.326

0.408

3

2

0.438

0.235-8.800

0.308

0.554

6

1/5

0100/1001

CTAC/TCAT

10

5

1.478

0.498-4.386

0.479

1

9

3

1.912

0.508-7.201

0.220

0.440

1

2

0.469

0.042-5.264

0.424

0.424

7

2/5

0000/1001

CCAC/TCAT

5

4

0.912

0.242-3.437

0.900

0.981

5

0

-

-

-

0

4

-

-

-

8

5/5

1001/1001

TCAT/TCAT

3

1

2.205

0.228-21.338

0.484

0.830

1

1

0.622

0.039-10.032

0.294

0.49

2

0

-

-

-

9

1/7

0100/1000

CTAC/TCAC

6

4

1.098

0.306-3.939

0.891

1

1

2

0.308

0.028-3.437

0.321

0.467

5

2

2.477

0.463-12.931

0.278

0.626

10

1/8

0100/1010

CTAC/TCCC

3

3

0.728

0.146-3.642

0.698

1

1

1

0.622

0.039-10.032

0.327

0.363

2

2

0.948

0.131-6.874

0.383

0.431

11

2/8

0000/1010

CCAC/TCCC

7

5

1.024

0.321-3.269

0.968

0.968

0

5

-

-

-

7

0

-

-

-

12

1/9

0100/1011

CTAC/TCCT

5

8

0.448

0.144-1.387

0.153

0.918

4

6

0.404

0.112-1.461

0.154

0.513

1

2

0.469

0.042-5.264

0.353

0.454